FR3014695A1 - - Google Patents

Download PDF

Info

Publication number: FR3014695A1
Authority: FR; France
Prior art keywords: human; pcsk9; seq; ligand; sequence
Prior art date: 2013-12-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

FR1362814A

Other languages

English (en)

French (fr)

Inventor

Jasper Clube

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kymab Ltd

Original Assignee

Kymab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-17

Filing date

2013-12-17

Publication date

2015-06-19

2013-12-17 Application filed by Kymab Ltd filed Critical Kymab Ltd

2013-12-17 Priority to FR1362814A priority Critical patent/FR3014695A1/fr

2014-06-16 Priority to EP14172579.6A priority patent/EP2886558A1/en

2014-06-16 Priority to EP14172578.8A priority patent/EP2886557A1/en

2015-06-19 Publication of FR3014695A1 publication Critical patent/FR3014695A1/fr

2016-03-18 Priority to FR1652328A priority patent/FR3033703A1/fr

Status Withdrawn legal-status Critical Current

Links

239000003446 ligand Substances 0.000 claims abstract description 419
241000282414 Homo sapiens Species 0.000 claims abstract description 389
238000000034 method Methods 0.000 claims abstract description 289
239000000203 mixture Substances 0.000 claims abstract description 41
102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 453
239000002773 nucleotide Substances 0.000 claims description 386
125000003729 nucleotide group Chemical group 0.000 claims description 386
230000027455 binding Effects 0.000 claims description 176
150000001413 amino acids Chemical class 0.000 claims description 144
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 144
125000003275 alpha amino acid group Chemical group 0.000 claims description 142
101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 139
201000010099 disease Diseases 0.000 claims description 126
230000003197 catalytic effect Effects 0.000 claims description 117
108090000623 proteins and genes Proteins 0.000 claims description 116
102000053786 human PCSK9 Human genes 0.000 claims description 105
210000004899 c-terminal region Anatomy 0.000 claims description 102
102000004169 proteins and genes Human genes 0.000 claims description 90
238000011282 treatment Methods 0.000 claims description 89
108090000765 processed proteins & peptides Proteins 0.000 claims description 81
150000007523 nucleic acids Chemical class 0.000 claims description 76
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 74
239000012634 fragment Substances 0.000 claims description 71
102000039446 nucleic acids Human genes 0.000 claims description 62
108020004707 nucleic acids Proteins 0.000 claims description 62
230000001404 mediated effect Effects 0.000 claims description 52
108091026890 Coding region Proteins 0.000 claims description 50
238000003205 genotyping method Methods 0.000 claims description 47
108010028554 LDL Cholesterol Proteins 0.000 claims description 41
210000004027 cell Anatomy 0.000 claims description 39
239000003814 drug Substances 0.000 claims description 39
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 32
239000008194 pharmaceutical composition Substances 0.000 claims description 32
208000035150 Hypercholesterolemia Diseases 0.000 claims description 31
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 31
230000000692 anti-sense effect Effects 0.000 claims description 31
238000004519 manufacturing process Methods 0.000 claims description 28
229940079593 drug Drugs 0.000 claims description 26
210000002966 serum Anatomy 0.000 claims description 26
238000002347 injection Methods 0.000 claims description 25
239000007924 injection Substances 0.000 claims description 25
230000002265 prevention Effects 0.000 claims description 24
230000008685 targeting Effects 0.000 claims description 23
208000029078 coronary artery disease Diseases 0.000 claims description 22
208000031226 Hyperlipidaemia Diseases 0.000 claims description 21
108010032595 Antibody Binding Sites Proteins 0.000 claims description 18
230000008569 process Effects 0.000 claims description 18
229960002027 evolocumab Drugs 0.000 claims description 17
230000005764 inhibitory process Effects 0.000 claims description 17
208000024172 Cardiovascular disease Diseases 0.000 claims description 16
206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 14
230000001225 therapeutic effect Effects 0.000 claims description 14
210000001519 tissue Anatomy 0.000 claims description 14
229960004539 alirocumab Drugs 0.000 claims description 13
238000008214 LDL Cholesterol Methods 0.000 claims description 12
238000003780 insertion Methods 0.000 claims description 12
230000037431 insertion Effects 0.000 claims description 12
238000012216 screening Methods 0.000 claims description 11
208000006011 Stroke Diseases 0.000 claims description 10
238000002955 isolation Methods 0.000 claims description 10
208000010125 myocardial infarction Diseases 0.000 claims description 10
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 8
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 8
229960005370 atorvastatin Drugs 0.000 claims description 8
230000003053 immunization Effects 0.000 claims description 8
210000003296 saliva Anatomy 0.000 claims description 8
210000002700 urine Anatomy 0.000 claims description 6
101150097493 D gene Proteins 0.000 claims description 5
210000004209 hair Anatomy 0.000 claims description 5
230000000069 prophylactic effect Effects 0.000 claims description 5
101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 4
230000000295 complement effect Effects 0.000 claims description 4
239000013604 expression vector Substances 0.000 claims description 4
238000005215 recombination Methods 0.000 claims description 4
230000006798 recombination Effects 0.000 claims description 4
108091005461 Nucleic proteins Proteins 0.000 claims description 3
229910052738 indium Inorganic materials 0.000 claims description 2
-1 kits Substances 0.000 abstract description 24
101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 421
235000001014 amino acid Nutrition 0.000 description 159
229940024606 amino acid Drugs 0.000 description 142
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 82
235000018102 proteins Nutrition 0.000 description 81
108700028369 Alleles Proteins 0.000 description 79
239000000523 sample Substances 0.000 description 67
102000036639 antigens Human genes 0.000 description 66
108091007433 antigens Proteins 0.000 description 66
239000000427 antigen Substances 0.000 description 65
241000282412 Homo Species 0.000 description 53
102000004196 processed proteins & peptides Human genes 0.000 description 45
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 44
229920001184 polypeptide Polymers 0.000 description 43
102000025171 antigen binding proteins Human genes 0.000 description 38
108091000831 antigen binding proteins Proteins 0.000 description 38
108010001831 LDL receptors Proteins 0.000 description 37
238000012360 testing method Methods 0.000 description 36
239000012472 biological sample Substances 0.000 description 35
238000006467 substitution reaction Methods 0.000 description 35
238000002560 therapeutic procedure Methods 0.000 description 33
238000003556 assay Methods 0.000 description 30
230000000694 effects Effects 0.000 description 30
229920002477 rna polymer Polymers 0.000 description 25
108020004705 Codon Proteins 0.000 description 23
235000012000 cholesterol Nutrition 0.000 description 23
102000053602 DNA Human genes 0.000 description 21
108020004414 DNA Proteins 0.000 description 21
238000004458 analytical method Methods 0.000 description 21
239000003795 chemical substances by application Substances 0.000 description 20
102000054766 genetic haplotypes Human genes 0.000 description 20
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 20
230000007423 decrease Effects 0.000 description 19
208000035475 disorder Diseases 0.000 description 18
238000005516 engineering process Methods 0.000 description 17
230000009467 reduction Effects 0.000 description 17
239000003550 marker Substances 0.000 description 16
238000003199 nucleic acid amplification method Methods 0.000 description 16
230000003321 amplification Effects 0.000 description 15
230000001186 cumulative effect Effects 0.000 description 15
108091028043 Nucleic acid sequence Proteins 0.000 description 14
241000700159 Rattus Species 0.000 description 14
239000000975 dye Substances 0.000 description 14
230000035772 mutation Effects 0.000 description 14
230000003472 neutralizing effect Effects 0.000 description 14
238000012163 sequencing technique Methods 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
238000003745 diagnosis Methods 0.000 description 13
201000001320 Atherosclerosis Diseases 0.000 description 12
208000032928 Dyslipidaemia Diseases 0.000 description 12
208000017170 Lipid metabolism disease Diseases 0.000 description 12
108020004459 Small interfering RNA Proteins 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
208000026758 coronary atherosclerosis Diseases 0.000 description 12
150000002632 lipids Chemical class 0.000 description 12
239000000047 product Substances 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
239000000758 substrate Substances 0.000 description 12
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 11
239000000872 buffer Substances 0.000 description 11
238000012217 deletion Methods 0.000 description 11
230000037430 deletion Effects 0.000 description 11
108010047041 Complementarity Determining Regions Proteins 0.000 description 10
108020004711 Nucleic Acid Probes Proteins 0.000 description 10
125000000539 amino acid group Chemical group 0.000 description 10
230000008859 change Effects 0.000 description 10
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
239000000463 material Substances 0.000 description 10
238000007481 next generation sequencing Methods 0.000 description 10
239000002853 nucleic acid probe Substances 0.000 description 10
239000012491 analyte Substances 0.000 description 9
230000008901 benefit Effects 0.000 description 9
230000006870 function Effects 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
238000011321 prophylaxis Methods 0.000 description 9
230000009870 specific binding Effects 0.000 description 9
239000000126 substance Substances 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
206010022562 Intermittent claudication Diseases 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 8
208000018262 Peripheral vascular disease Diseases 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
208000024980 claudication Diseases 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
208000020346 hyperlipoproteinemia Diseases 0.000 description 8
239000002904 solvent Substances 0.000 description 8
241000894007 species Species 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 7
108010023302 HDL Cholesterol Proteins 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000001514 detection method Methods 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
102000054765 polymorphisms of proteins Human genes 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
206010020772 Hypertension Diseases 0.000 description 6
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 6
108020005187 Oligonucleotide Probes Proteins 0.000 description 6
241000288906 Primates Species 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
238000009826 distribution Methods 0.000 description 6
229960003765 fluvastatin Drugs 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
229960004844 lovastatin Drugs 0.000 description 6
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 6
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 6
239000002751 oligonucleotide probe Substances 0.000 description 6
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
229960002855 simvastatin Drugs 0.000 description 6
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
229910052717 sulfur Inorganic materials 0.000 description 6
102100040202 Apolipoprotein B-100 Human genes 0.000 description 5
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
108010007622 LDL Lipoproteins Proteins 0.000 description 5
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 5
108090000787 Subtilisin Proteins 0.000 description 5
238000007792 addition Methods 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
238000013475 authorization Methods 0.000 description 5
238000005844 autocatalytic reaction Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
201000001386 familial hypercholesterolemia Diseases 0.000 description 5
239000007850 fluorescent dye Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000013595 glycosylation Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
238000005259 measurement Methods 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
238000007899 nucleic acid hybridization Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229960002797 pitavastatin Drugs 0.000 description 5
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 5
229960002965 pravastatin Drugs 0.000 description 5
238000000159 protein binding assay Methods 0.000 description 5
229960000672 rosuvastatin Drugs 0.000 description 5
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 5
230000007017 scission Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 4
206010008635 Cholestasis Diseases 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
206010029164 Nephrotic syndrome Diseases 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
208000008589 Obesity Diseases 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
102000012479 Serine Proteases Human genes 0.000 description 4
108010022999 Serine Proteases Proteins 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
241000251539 Vertebrata <Metazoa> Species 0.000 description 4
230000009102 absorption Effects 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
229960005110 cerivastatin Drugs 0.000 description 4
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
239000003599 detergent Substances 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000005714 functional activity Effects 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
208000003532 hypothyroidism Diseases 0.000 description 4
230000002989 hypothyroidism Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
238000006386 neutralization reaction Methods 0.000 description 4
229960003512 nicotinic acid Drugs 0.000 description 4
235000001968 nicotinic acid Nutrition 0.000 description 4
239000011664 nicotinic acid Substances 0.000 description 4
235000020824 obesity Nutrition 0.000 description 4
238000002823 phage display Methods 0.000 description 4
229910052698 phosphorus Inorganic materials 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
239000004474 valine Substances 0.000 description 4
229960004295 valine Drugs 0.000 description 4
239000002699 waste material Substances 0.000 description 4
102220560278 ATP-dependent RNA helicase DDX1_K52N_mutation Human genes 0.000 description 3
101710095342 Apolipoprotein B Proteins 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
102000003839 Human Proteins Human genes 0.000 description 3
108090000144 Human Proteins Proteins 0.000 description 3
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 3
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
101710172072 Kexin Proteins 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
241000282567 Macaca fascicularis Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
102000004316 Oxidoreductases Human genes 0.000 description 3
108090000854 Oxidoreductases Proteins 0.000 description 3
101150094724 PCSK9 gene Proteins 0.000 description 3
102000006437 Proprotein Convertases Human genes 0.000 description 3
108010044159 Proprotein Convertases Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000002617 apheresis Methods 0.000 description 3
230000003190 augmentative effect Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
108091008324 binding proteins Proteins 0.000 description 3
108020001778 catalytic domains Proteins 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000007614 genetic variation Effects 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000000126 in silico method Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
239000002502 liposome Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000002245 particle Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
238000002702 ribosome display Methods 0.000 description 3
102220238658 rs1468529365 Human genes 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
238000010257 thawing Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 3
RZPAXNJLEKLXNO-UKNNTIGFSA-N 22-Hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C(O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-UKNNTIGFSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
208000027796 Blood pressure disease Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
101710112752 Cytotoxin Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000010911 Enzyme Precursors Human genes 0.000 description 2
108010062466 Enzyme Precursors Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
102000004961 Furin Human genes 0.000 description 2
108090001126 Furin Proteins 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 2
102100037732 Neuroendocrine convertase 2 Human genes 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
241000009328 Perro Species 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
108010022052 Proprotein Convertase 5 Proteins 0.000 description 2
101710180647 Proprotein convertase subtilisin/kexin type 7 Proteins 0.000 description 2
208000030555 Pygmy Diseases 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
108010003723 Single-Domain Antibodies Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000001261 affinity purification Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
239000003524 antilipemic agent Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
239000011805 ball Substances 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
239000005516 coenzyme A Substances 0.000 description 2
229940093530 coenzyme a Drugs 0.000 description 2
230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
239000002619 cytotoxin Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000002716 delivery method Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
125000002228 disulfide group Chemical group 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229960000815 ezetimibe Drugs 0.000 description 2
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000012520 frozen sample Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000036963 noncompetitive effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
210000003720 plasmablast Anatomy 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229940068977 polysorbate 20 Drugs 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
108020001580 protein domains Proteins 0.000 description 2
238000002818 protein evolution Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000012175 pyrosequencing Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000009103 reabsorption Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
102220117530 rs112626848 Human genes 0.000 description 2
102200148758 rs116840795 Human genes 0.000 description 2
238000007480 sanger sequencing Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
229940043263 traditional drug Drugs 0.000 description 2
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229910052720 vanadium Inorganic materials 0.000 description 2
238000012795 verification Methods 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 1
VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
101710111216 Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 description 1
108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000282672 Ateles sp. Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
101100229711 Caenorhabditis elegans eas-1 gene Proteins 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
244000175448 Citrus madurensis Species 0.000 description 1
235000004332 Citrus madurensis Nutrition 0.000 description 1
235000007438 Citrus mitis Nutrition 0.000 description 1
241001672694 Citrus reticulata Species 0.000 description 1
229920002905 Colesevelam Polymers 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
230000009946 DNA mutation Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
241000252212 Danio rerio Species 0.000 description 1
101100239628 Danio rerio myca gene Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
101100001671 Emericella variicolor andF gene Proteins 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
108010008177 Fd immunoglobulins Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108090000652 Flap endonucleases Proteins 0.000 description 1
102000004150 Flap endonucleases Human genes 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
101000601394 Homo sapiens Neuroendocrine convertase 2 Proteins 0.000 description 1
101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 1
208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 description 1
238000012450 HuMAb Mouse Methods 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108010065920 Insulin Lispro Proteins 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
241000721701 Lynx Species 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
102100034028 Membrane-bound transcription factor site-1 protease Human genes 0.000 description 1
101710193467 Membrane-bound transcription factor site-1 protease Proteins 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
108010006519 Molecular Chaperones Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101001128692 Mus musculus Neuroendocrine convertase 1 Proteins 0.000 description 1
101000763311 Mus musculus Thrombomodulin Proteins 0.000 description 1
241000282339 Mustela Species 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
101710151472 Neuroendocrine convertase 1 Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282579 Pan Species 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108010010677 Phosphodiesterase I Proteins 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
241000364051 Pima Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
108090000545 Proprotein Convertase 2 Proteins 0.000 description 1
102000012210 Proprotein Convertase 5 Human genes 0.000 description 1
108090000544 Proprotein convertase 1 Proteins 0.000 description 1
102100036371 Proprotein convertase subtilisin/kexin type 4 Human genes 0.000 description 1
101710180646 Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 1
102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102220572938 RNA-binding protein FUS_L18M_mutation Human genes 0.000 description 1
238000011529 RT qPCR Methods 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
241001669494 Rice stripe mosaic virus Species 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
DMWVGXGXHPOEPT-UHFFFAOYSA-N Src Inhibitor-1 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 DMWVGXGXHPOEPT-UHFFFAOYSA-N 0.000 description 1
108010088160 Staphylococcal Protein A Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101710135785 Subtilisin-like protease Proteins 0.000 description 1
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
101100108068 Zea mays TPS1 gene Proteins 0.000 description 1
PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
229940125710 antiobesity agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
229930002875 chlorophyll Natural products 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
230000007870 cholestasis Effects 0.000 description 1
231100000359 cholestasis Toxicity 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
239000003245 coal Substances 0.000 description 1
229960001152 colesevelam Drugs 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000005056 compaction Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
150000004775 coumarins Chemical class 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
102000054767 gene variant Human genes 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
231100000640 hair analysis Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012165 high-throughput sequencing Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
229940038661 humalog Drugs 0.000 description 1
229940062714 humalog mix Drugs 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
238000012004 kinetic exclusion assay Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
229940095570 lescol Drugs 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940092923 livalo Drugs 0.000 description 1
230000003908 liver function Effects 0.000 description 1
KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000010208 microarray analysis Methods 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
102000022026 mismatched DNA binding proteins Human genes 0.000 description 1
108091012361 mismatched DNA binding proteins Proteins 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000011807 nanoball Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000009223 neuronal apoptosis Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
239000006014 omega-3 oil Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000011338 personalized therapy Methods 0.000 description 1
230000002974 pharmacogenomic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940089484 pravachol Drugs 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
238000004451 qualitative analysis Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
102220220520 rs1060503090 Human genes 0.000 description 1
102200057361 rs11583680 Human genes 0.000 description 1
102200032481 rs1403626 Human genes 0.000 description 1
102220325921 rs1555376589 Human genes 0.000 description 1
102220142694 rs192332456 Human genes 0.000 description 1
102200164344 rs63751661 Human genes 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000037432 silent mutation Effects 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
ITAWMPSVROAMOE-UHFFFAOYSA-N sodium;imidazol-3-ide Chemical compound [Na+].C1=C[N-]C=N1 ITAWMPSVROAMOE-UHFFFAOYSA-N 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000000123 temperature gradient gel electrophoresis Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
108010093297 tetrapeptide carbamate Proteins 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
238000012876 topography Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

FR1362814A 2013-12-17 2013-12-17 Withdrawn FR3014695A1 (es)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
FR1362814A FR3014695A1 (es)	2013-12-17	2013-12-17
EP14172579.6A EP2886558A1 (en)	2013-12-17	2014-06-16	Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP14172578.8A EP2886557A1 (en)	2013-12-17	2014-06-16	Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
FR1652328A FR3033703A1 (es)	2013-12-17	2016-03-18

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1362814A FR3014695A1 (es)	2013-12-17	2013-12-17

Publications (1)

Publication Number	Publication Date
FR3014695A1 true FR3014695A1 (es)	2015-06-19

Family

ID=51292991

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR1362814A Withdrawn FR3014695A1 (es)	2013-12-17	2013-12-17
FR1652328A Withdrawn FR3033703A1 (es)	2013-12-17	2016-03-18

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FR1652328A Withdrawn FR3033703A1 (es)	2013-12-17	2016-03-18

Country Status (1)

Country	Link
FR (2)	FR3014695A1 (es)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004097047A1 (en) *	2003-04-25	2004-11-11	Institut National de la Santé et de la Recherche Médicale	Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2008011431A2 (en) *	2006-07-17	2008-01-24	Sirna Therapeutics Inc.	Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2009026558A1 (en) *	2007-08-23	2009-02-26	Amgen Inc.	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2011072263A1 (en) *	2009-12-11	2011-06-16	Irm Llc	Pcsk9 antagonists
WO2012088313A1 (en) *	2010-12-22	2012-06-28	Genentech, Inc.	Anti-pcsk9 antibodies and methods of use

2013
- 2013-12-17 FR FR1362814A patent/FR3014695A1/fr not_active Withdrawn
2016
- 2016-03-18 FR FR1652328A patent/FR3033703A1/fr not_active Withdrawn

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004097047A1 (en) *	2003-04-25	2004-11-11	Institut National de la Santé et de la Recherche Médicale	Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2008011431A2 (en) *	2006-07-17	2008-01-24	Sirna Therapeutics Inc.	Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2009026558A1 (en) *	2007-08-23	2009-02-26	Amgen Inc.	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2011072263A1 (en) *	2009-12-11	2011-06-16	Irm Llc	Pcsk9 antagonists
WO2012088313A1 (en) *	2010-12-22	2012-06-28	Genentech, Inc.	Anti-pcsk9 antibodies and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVIGNON J ET AL: "The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis", CURRENT ATHEROSCLEROSIS REPORTS, CURRENT SCIENCE, US, vol. 12, no. 5, 1 September 2010 (2010-09-01), pages 308 - 315, XP009163743, ISSN: 1523-3804, DOI: 10.1007/S11883-010-0123-6 *
HOPKINS PAUL N ET AL: "A Randomized Placebo-phase Clinical Trial With the Monoclonal Antibody Alirocumab Demonstrates Reductions in Low-density Lipoprotein Cholesterol in Patients With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function Mutations", CIRCULATION, vol. 128, no. 22, Suppl. S, November 2013 (2013-11-01), & SCIENTIFIC SESSIONS AND RESUSCITATION SCIENCE SYMPOSIUM OF THE AMERICAN-HEART-ASSOCIATION; DALLAS, TX, USA; NOVEMBER 16 -17, 2013, pages 17156, XP002730991 *
JANICE MAYNE ET AL: "Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations", LIPIDS IN HEALTH AND DISEASE, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 10 May 2013 (2013-05-10), pages 70, XP021151113, ISSN: 1476-511X, DOI: 10.1186/1476-511X-12-70 *
KOTOWSKI I K ET AL: "A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 78, no. 3, 1 March 2006 (2006-03-01), pages 410 - 422, XP008100000, ISSN: 0002-9297 *
LI SHEN ET AL: "The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors", PHARMACOLOGICAL RESEARCH., vol. 73, 1 July 2013 (2013-07-01), GB, pages 27 - 34, XP055139387, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2013.04.001 *

Also Published As

Publication number	Publication date
FR3033703A1 (es)	2016-09-23

Publication	Publication Date	Title
US11434305B2 (en)	2022-09-06	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en)	2015-05-19	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
WO2015092394A1 (en)	2015-06-25	Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
DE112014005747T5 (de)	2016-10-06	Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen
US9034331B1 (en)	2015-05-19	Targeting rare human PCSK9 variants for cholesterol treatment
JP2018203772A (ja)	2018-12-27	被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体
JP2019514907A (ja)	2019-06-06	家族性高コレステロール血症を有する患者を処置するための方法
JP2022078306A (ja)	2022-05-24	Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
SA515360248B1 (ar)	2017-02-20	أجسام مضادة cd26 واستخداماتها
US9045548B1 (en)	2015-06-02	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en)	2015-06-09	Targeting rare human PCSK9 variants for cholesterol treatment
EP2886557A1 (en)	2015-06-24	Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
FR3014695A1 (es)	2015-06-19
EP2975059A1 (en)	2016-01-20	Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP2975058A1 (en)	2016-01-20	Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP4328245A2 (en)	2024-02-28	Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
TW201525005A (zh)	2015-07-01	用於膽固醇治療之標靶人類第９型前蛋白轉換酶枯草桿菌蛋白酶（ｐｃｓｋ９）之技術
DE202015009002U1 (de)	2016-08-18	Targeting von humaner PCSK9 zur Cholesterinbehandlung
DE202014010499U1 (de)	2015-10-20	Targeting von humaner PCSK9 zur Cholesterinbehandlung
IES20140279A2 (en)	2015-06-17	Human targets II
IES86600B2 (en)	2015-11-18	An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level
GB2558442A (en)	2018-07-11	Human targets II
IES20140321A2 (en)	2016-01-27	An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level

Legal Events

Date	Code	Title	Description
2015-12-17	PLFP	Fee payment	Year of fee payment: 3
2016-12-27	PLFP	Fee payment	Year of fee payment: 4
2017-12-27	PLFP	Fee payment	Year of fee payment: 5
2019-09-27	ST	Notification of lapse	Effective date: 20190906